Heinemann Lutz
Science Consulting in Diabetes GmbH, Düsseldorf, Germany.
J Diabetes Sci Technol. 2024 Dec 13:19322968241305383. doi: 10.1177/19322968241305383.
Millions of people with diabetes have no or only limited access to electricity that limits their ability to store insulin according to the recommendations of the insulin manufacturer in general. At the same time, environmental temperatures are increasing in many countries which have a negative impact on the glucose-lowering effect of insulin not stored adequately. Therefore, the availability of heat-stable insulin formulations that do not require constant cooling would be of help for many patients; however, despite this clinical need, apparently not many are in clinical development. This commentary discusses the different aspects and approaches that are of relevance in this context.
数以百万计的糖尿病患者无法获得电力或只能获得有限的电力，这总体上限制了他们按照胰岛素制造商的建议储存胰岛素的能力。与此同时，许多国家的环境温度正在上升，这对未充分储存的胰岛素的降糖效果产生负面影响。因此，不需要持续冷藏的热稳定胰岛素制剂的可用性将对许多患者有所帮助；然而，尽管有这种临床需求，但显然目前处于临床开发阶段的此类制剂并不多。本评论讨论了在这种情况下相关的不同方面和方法。
